BLUE BIOFUELS, INC. - Annual Report: 2017 (Form 10-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

Annual Report Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934

for the fiscal year ended December 31, 2017

Transition Report Under Section 13 or 15(D) of the Securities Exchange Act of 1934

for the transition period from _______________ to _______________

Commission File Number: 333-181633

ALLIANCE BIOENERGY PLUS, INC.

(Exact name of small Business Issuer as specified in its charter)

Nevada		45-4944960
(State or other jurisdiction of		(IRS Employer Identification No.)
incorporation or organization)

400 N. Congress Avenue, Suite 130
West Palm Beach, FL		33401
(Address of principal executive offices)		(Zip Code)

Issuer’s telephone number, including area code: (888) 607-3555

n/a

Former address if changed since last report

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value $0.001 per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X].

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-K contained in this form, and no disclosure will be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ]

Accelerated Filer [ ]

Non-Accelerated Filer [ ] (Do not check if a smaller reporting company)

Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter (June 30, 2017): $35,757,884

State the number of shares outstanding of the registrant's $.001 par value common stock as of the close of business on the latest practicable date (April 17, 2018): 129,406,233

Documents incorporated by reference: None.

TABLE OF CONTENTS

PART I

ITEM 1.	Business	3

ITEM 1A.	Risk Factors	4

ITEM 1B.	Unresolved Staff Comments	4

ITEM 2.	Properties	4

ITEM 3.	Legal Proceedings	5

ITEM 4.	Mine Safety Disclosures	5

PART II

ITEM 5.	Market For Registrants Common Equity; Related Stockholder Matters and Issuer Purchases of Equity Securities	5

ITEM 6.	Selected Financial Data	10

ITEM 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	10

ITEM 7A.	Quantitative and Qualitative Disclosure About Market Risk	16

ITEM 8.	Financial Statements and Supplementary Data	16

ITEM 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	17

ITEM 9A.	Controls and Procedures	17

ITEM 9B.	Other Information	19

PART III

ITEM 10	Directors, Executive Officers and Corporate Governance	19

ITEM 11.	Executive Compensation	21

ITEM 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters	23

ITEM 13.	Certain Relationships and Related Transactions and Director Independence	24

ITEM 14.	Principal Accountant Fees and Services	25

PART IV

ITEM 15.	Exhibits, Financial Statement Schedules	26

SIGNATURES		27

FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K (the “Report”), including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of Alliance BioEnergy Plus, Inc. and its consolidated subsidiaries (the “Company”) that are based on management’s current expectations, estimates, projections and assumptions about the Company’s business. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “sees,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including, but not limited to, those discussed in the “Risk Factors” section in Item 1A, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and elsewhere in this Report as well as those discussed from time to time in the Company’s other Securities and Exchange Commission filings and reports. In addition, such statements could be affected by general industry and market conditions. Such forward-looking statements speak only as of the date of this Report or, in the case of any document incorporated by reference, the date of that document, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Report. If we update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections with respect to other forward-looking statements.

PART I

ITEM 1. BUSINESS

Background

Business Overview

Alliance Bioenergy Plus, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels, and new technologies sectors. From inception through December 5, 2014, the Company was known as Alliance Media Group Holdings, Inc. At inception (March 28, 2012), the Company was organized as a vehicle to engage in the commercial production, distribution and exploitation of Motion Pictures and other Entertainment products. However, in December 2013, a wholly owned subsidiary of the Company, AMG Renewables, LLC (“AMG Renewables”), acquired the controlling interest (51%) in AMG Energy Group, LLC (“AMG Energy”), which owns a fifty percent (50%) interest in Carbolosic, LLC (“Carbolosic”). Carbolosic holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™.” The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The Company’s goal in acquiring the interest in AMG Energy was to develop the CTS technology to a commercial scale and then seek to license the technology to prospective licensees. In September 2014, the Company determined to focus all of the Company’s resources and personnel on the Company’s renewable energy holdings and future energy technologies and to divest the Company of its entertainment-related assets and subsidiaries. Effective December 5, 2014, amended the Company’s Articles of Incorporation to change the name of the Company to Alliance Bioenergy Plus, Inc., which more appropriately describes the Company’s new business direction.

In December 2014, AMG Energy formed EK Laboratories, Inc. (originally, Central Florida Institute of Science and Technology, Inc.) (“EK”), to serve as a demonstration and research facility to further develop the CTS process, its uses, and develop new technologies. EK remains a wholly-owned subsidiary of AMG Energy.

In July 2016, the Company determined to restructure its energy holdings under a single wholly-owned subsidiary (AMG Energy) such that AMG Energy would own (i) the Company’s fifty percent (50%) interest of Carbolosic (which includes certain licensing rights in North America and Africa) and (ii) the Company’s 100% interest in EK Laboratories, LLC. This restructuring was completed on September 19, 2016 when AMG Renewables merged into AMG Energy. Previously, the Company had completed transactions with certain related parties to acquire the remaining 49% of AMG Energy, which was not owned by the Company, in exchange for an aggregate of 10,240,094 shares of Company common stock and a restructuring of the balance due under a cash payable to the minority AMG Energy Shareholders.

The Company is now focused on the development and commercialization of the licensed technology it controls through its affiliate Carbolosic, LLC. Through its wholly-owned subsidiary, AMG Energy, the Company owns Ek Laboratories, Inc. and a 50% interest in Carbolosic (which includes certain licensing rights in North America and Africa).

The Company has a strategy that includes mergers and acquisitions of existing businesses in the renewable energy and sustainable products industries as well as sublicensing its patented technologies that it controls through a master license with the University of Central Florida under affiliate Carbolosic and start-up activities which are focused on development of an increasing revenue stream, secure market share and enhancement of shareholder value.

In February 2017, the Company formed Alliance Bio-Products, Inc., a Florida corporation (“ABIOP”), for the purpose of acquiring and operating a plant for the installation of the Company’s patented CTS process. The Company intends to raise money into ABIOP for this purpose.

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization as well as the bio-fuels, renewable energy, chemical manufacturing and engineering and industrial construction industries. As of this date, the Company has not generated any revenues from its business.

Description of the Company’s Securities

The Company is currently authorized to issue 500,000,000 Shares of Common Stock par value $0.001 and 10,000,000 shares of Preferred Stock par value $0.001. Each share of Company Common Stock is entitled to one (1) vote per share.

Employees

The company currently employs eight full-time employees, one part-time employee and two consultants.

ITEM 1A. RISK FACTORS

Not required as the Company is a “smaller reporting company.”

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Offices

The Company maintains its corporate office at 400 N Congress Avenue, Suite 130, West Palm Beach Florida 33401. The Company’s telephone number is 888-607-3555. In August 2015, the Company renewed its lease for a period of thirty-six (36) months from August 5, 2015 through July 31, 2018. Annual rent commenced at approximately $48,925 per annum and increases on a year-to-year basis by three percent (3%) over the base year. In addition, the Company is obligated to pay an amount equal to 3.76% of the operating expenses of the building together with sales tax on all amounts.

EK Laboratories leased office and warehouse space in Longwood, FL, which served as the Company’s research and demonstration facility. The lease period was for thirty-six (36) months from February 1, 2015 through January 31, 2018. Annual rent commenced at approximately $70,620 per annum and increased on a year-to-year basis by five percent (5%) over the prior year. The lease was not renewed.

EK Laboratories leases office and warehouse space in Royal Palm Beach, FL, which serves as the Company’s research and demonstration facility. The lease period is for thirty-six (36) months from December 1, 2017 through January 31, 2020. Annual rent commences at approximately $32,400 per annum and increases on a year-to-year basis by three percent (3.0%) over the prior year.

ITEM 3. LEGAL PROCEEDINGS

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY; RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market for Registrant’s Common Equity

The Company became subject to Securities Exchange Act Reporting Requirements in October 2012. The symbol “ALLM” is assigned for its securities. The Company’s common stock commenced trading on the OTCBB on February 5, 2014.

The following table shows the high and low prices of the Company’s common shares on the OTC Bulletin Board for each quarter since January 1, 2015. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions:

	2015				2016				2017				2018
PERIOD	High		Low		High		Low		High		Low		High		Low
JAN 1^st – MAR 31^st	$	0.65	$	0.22	$	0.42	$	0.15	$	0.23	$	0.11	$	0.06	$	0.02
APR 1^st – JUN 30^th	$	1.39	$	0.07	$	0.45	$	0.06	$	0.40	$	0.10
JUL 1^st – SEP 30^th	$	0.68	$	0.30	$	0.42	$	0.15	$	0.39	$	0.14
OCT 1^st – DEC 31^st	$	0.55	$	0.28	$	0.27	$	0.18	$	0.20	$	0.02

Options and Warrants

In February 2015, the Company began a second round of financing wherein each unit sold consists of one (1) share of common stock, one (1) series A Warrant for a period of three (3) years convertible to .5 Common Share at an exercise price of $0.75 and one (1) series B Warrant for a period of three (3) years convertible to .5 Common Share at an exercise price of $1.50. Through this offering the Company had sold 2,460,202 units, however 1,687,702 warrants have since expired.

In November 2015, the Company began a third round of financing wherein each unit sold consists of one (1) share of common stock, one (1) series C Warrant for a period of three (3) years convertible to .5 common share at an exercise price of $0.45 and one (1) series D Warrant for a period of three (3) years convertible to .5 common share at an exercise price of $0.65. Through this offering the Company has sold 1,460,898 units.

In January 2016, the Company began a fourth round of financing wherein each unit consist of one (1) share of common stock and one (1) series E warrant for a period of five (5) years convertible into one (1) share of common stock at an exercise price of $0.45 per share. Through this offering the Company has sold 4,535,517 units.

In March 2016, the Company began a fifth round of financing wherein each unit consist of three million seven hundred seventeen thousand seven hundred eighty-five (3,717,785) shares of common stock and four million five hundred thousand (4,500,000) series F warrants for a period of five (5) years at an exercise price of $0.25 per share. Each warrant is convertible into one (1) share of common stock. Each unit also has an antidilution protection clause of no more than 10%. Through this offering the Company has sold 2 units. In December 2017, an additional 12,739,976 warrants were issued as a result of the antidilution protection clause.

In October 2016, the Company began a sixth round of financing wherein each unit consist of one (1) share of common stock and one (1) series E warrant for a period of five (5) years convertible into one (1) share of common stock at an exercise price of $0.45 per share. Through this offering the Company has sold 6,887,550 units.

In March 2015, the Company’s Board of Directors approved a resolution to compensate the board’s independent directors with cash or equity per quarter under the Company’s 2012 Employee, Director Stock Plan. Through the date of filing, the company has issued option agreements to its independent directors and employees, to purchase an aggregate of 40,091,776 shares of common stock ranging from three (3) to ten (10) years, with exercise prices ranging from $0.03 to $0.16.

Through the date of filing, the Company has issued warrants to purchase an aggregate of 10,630.000 shares of common stock. The exercise prices associated with these agreements range from $0.13 to $2.00 and terms range from three (3) to five (5) years.

Other than the foregoing agreements, none of the Company’s shares of Common Stock are subject to outstanding options or warrants.

Holders

As of the date of filing, there were 129,406,233 shares of common stock outstanding and approximately 326 stockholders of record

Transfer Agent and Registrar

The Company’s transfer agent is Interwest Transfer Co., Inc., 1981 East 4800 South, Suite 100, Salt Lake City, UT, Phone: 801-272-9294.

Dividend Policy

The Company has never paid any cash dividends on its Common Stock and does not anticipate paying any cash dividends on its Common Stock in the foreseeable future. The Company intends to retain future earnings to fund ongoing operations and future capital requirements of its business. Any future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon the Company’s financial condition, results of operations, capital requirements and such other factors as the Board of Directors deems relevant.

Securities Authorized for Issuance Under Equity Compensation Plans

There are currently fully earned and vested option agreements in place to purchase an aggregate of 40,091,776 shares of common stock under the Company’s 2012 Employee, Director Stock Plan and there are additional agreements vesting over the next 5 years to purchase an additional 6,000,000 shares of common stock. In addition, 500,000 shares of common stock had been issued under the plan to a former employee, however these shares were rescinded in March 2017. At December 31, 2016, the Company option agreements in place to purchase an aggregate of 4,714,413 shares of common.

Plan Category	Minimum number of securities reserved under equity compensation plan		Exercise price of outstanding options, warrants and rights		Number of securities to be issued upon exercise of outstanding options, warrants and rights
	(a)		(b)		(c)
Equity compensation plans approved by security holders		21,626,255		$0.03 - $0.16		40,091,776
Equity compensation plans not approved by security holders		-0-		-0-		-0-
Total		21,626,255		$0.03 - $0.16		40,091,776

Recent Sales of Unregistered Securities

Below is a list of securities sold by the Company from January 1, 2017 through the date of filing which were not registered under the Securities Act.

Name of Purchaser

Date of Sale

Title of Security

Amount of Securities Sold

Consideration

Joseph A Galbo

01/01/17

Common Stock

12,500

Professional Services

Freedom Investors Corp

01/01/17

Common Stock

20,000

Professional Services

Luna Consultant Group, LLC

01/27/17

Common Stock

500,000

Professional Services

Major League Services Investment & Holdings Corp.

01/30/17

Common Stock

62,500

Purchased @ $0.20 per share

Gretchen Hickman

01/31/17

Common Stock

25,000

Purchased @ $0.20 per share

Nadia Marrese

01/31/17

Common Stock

25,000

Purchased @ $0.20 per share

Harry Grossman

01/31/17

Common Stock

8,000

Professional Services

Ken Hickman

01/31/17

Common Stock

2,500

Professional Services

Joseph A Galbo

02/01/17

Common Stock

12,500

Professional Services

Freedom Investors Corp

02/01/17

Common Stock

20,000

Professional Services

Lucas Hoppel

02/02/17

Common Stock

150,000

Inducement to secure a debt note

Harry Grossman

02/28/17

Common Stock

8,000

Professional Services

Joseph A Galbo

03/01/17

Common Stock

12,500

Professional Services

Freedom Investors Corp

03/01/17

Common Stock

20,000

Professional Services

David Matthews

03/10/17

Common Stock

(500,000

)

Rescinded Employment Stock

Steven Tureff & Donnis Newman

03/20/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

03/20/17

Common Stock

3,571

Professional Services

Harry Grossman

03/31/17

Common Stock

8,000

Professional Services

Joseph A Galbo

04/01/17

Common Stock

12,500

Professional Services

Freedom Investors Corp

04/01/17

Common Stock

20,000

Professional Services

John Cannon

04/17/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

04/17/17

Common Stock

1,471

Professional Services

Porter, LeVay & Rose, Inc.

04/17/17

Common Stock

100,000

Professional Services

Minal Patel

04/24/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

04/24/17

Common Stock

3,571

Professional Services

Martin Weinstein

04/25/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

04/25/17

Common Stock

3,847

Professional Services

Harry Grossman

04/30/17

Common Stock

8,000

Professional Services

Freedom Investors Corp

05/01/17

Common Stock

20,000

Professional Services

Nadia Marrese

05/03/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

05/03/17

Common stock

1,786

Professional Services

Edward Peters

05/19/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

05/19/17

Common Stock

3,572

Professional Services

Harry Grossman

05/31/17

Common Stock

8,000

Professional Services

AES Capital Partners, LP

06/02/17

Common Stock

100,000

Professional Services

John D. Lane

06/02/17

Common Stock

250,000

Professional Services

The AES Capital Resource Fund, L.P.

06/14/17

Common Stock

2,500,000

Purchased @ $0.20 per share

Martin Weinstein

06/15/17

Common stock

25,000

Purchased @ $0.20 per share

Ken Hickman

06/15/17

Common Stock

1,250

Professional Services

Nadia Marrese

06/24/17

Common Stock

50,000

Purchased @ $0.20 per share

Bryan White

06/26/17

Common Stock

50,000

Purchased @ $0.20 per share

Michael Geisler

06/26/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

06/26/17

Common Stock

4,287

Professional Services

Luna Consultant Group, LLC

06/27/17

Common Stock

500,000

Professional Services

Harry Grossman

06/30/17

Common Stock

8,000

Professional Services

JMJ Financial

06/30/17

Common Stock

1,340,201

Cashless Warrant Exercise

John D. Lane

07/01/17

Common Stock

10,000

Professional Services

Lucas Hoppel

07/03/17

Common Stock

150,000

Inducement to secure a debt note

Gretchen Hickman

07/10/17

Common Stock

25,000

Purchased @ $0.20 per share

Bryan White

07/13/17

Common Stock

50,000

Purchased @ $0.20 per share

Donnis Newman

07/13/17

Common Stock

25,000

Purchased @ $0.20 per share

Nadia Marrese

07/13/17

Common Stock

25,000

Purchased @ $0.20 per share

Steven Tureff

07/13/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

07/13/17

Common Stock

4,897

Professional Services

Deanna Hern

07/14/17

Common stock

25,000

Purchased @ $0.20 per share

Ken Hickman

07/19/17

Common Stock

758

Professional Services

Camilla Blaffer

07/24/17

Common Stock

150,000

Purchased @ $0.20 per share

Ken Hickman

07/24/17

Common Stock

6,522

Professional Services

John D. Lane

08/01/17

Common Stock

10,000

Professional Services

Freedom Investors Corp

08/01/17

Common Stock

20,000

Professional Services

Anthony Santelli, II

08/10/17

Common Stock

125,000

Purchased @ $0.20 per share

The AES Capital Resource Fund, LP

08/10/17

Common Stock

625,000

Purchased @ $0.20 per share

Lucas Hoppel

08/24/17

Common Stock

100,000

Convertible Debt Conversion

Lucas Hoppel

08/28/17

Common Stock

200,000

Convertible Debt Conversion

John D. Lane

09/01/17

Common Stock

10,000

Professional Services

Freedom Investors Corp

09/01/17

Common Stock

20,000

Professional Services

Lucas Hoppel

09/06/17

Common Stock

300,000

Convertible Debt Conversion

JMJ Financial

09/06/17

Common Stock

1,939,934

Convertible Debt Conversion

Steven Sadaka

09/15/17

Common Stock

500,000

Purchased @ $0.20 per share

Lucas Hoppel

09/20/17

Common Stock

300,000

Convertible Debt Conversion

John D. Lane

10/01/17

Common Stock

10,000

Professional Services

Lucas Hoppel

10/16/17

Common Stock

300,000

Convertible Debt Conversion

Lucas Hoppel

10/23/17

Common Stock

400,000

Convertible Debt Conversion

Auctus Fund

10/23/17

Common Stock

500,000

Convertible Debt Conversion

EMA Financial

10/23/17

Common Stock

250,000

Convertible Debt Conversion

Zac Bindler

10/23/17

Common Stock

50,000

Purchased @ $0.20 per share

Annie Bindler

10/23/17

Common Stock

50,000

Purchased @ $0.20 per share

EMA Financial

10/26/17

Commons Stock

325,000

Convertible Debt Conversion

Lucas Hoppel

10/27/17

Common Stock

360,991

Convertible Debt Conversion

JMJ Financial

10/31/17

Common Stock

(1,939,934

)

Rescinded Conversion

JMJ Financial

10/31/17

Common Stock

770,000

Convertible Debt Conversion

John D. Lane

11/01/17

Common Stock

10,000

Professional Services

EMA Financial

11/06/17

Common Stock

325,000

Convertible Debt Conversion

Auctus Fund

11/07/17

Common Stock

600,000

Convertible Debt Conversion

Crown Bridge Partners, LLC

11/16/17

Common Stock

130,000

Convertible Debt Conversion

Crown Bridge Partners, LLC

11/20/17

Common Stock

230,000

Convertible Debt Conversion

EMA Financial

11/20/17

Common Stock

250,000

Convertible Debt Conversion

Lucas Hoppel

11/20/17

Common Stock

500,000

Inducement to secure a debt note

Lucas Hoppel

11/22/17

Common Stock

500,000

Convertible Debt Conversion

EMA Financial

11/29/17

Common Stock

300,000

Convertible Debt Conversion

Auctus Fund

11/30/17

Common Stock

600,000

Convertible Debt Conversion

Lucas Hoppel

11/30/17

Common Stock

750,000

Convertible Debt Conversion

John D. Lane

12/01/17

Common Stock

10,000

Professional Services

Crown Bridge Partners, LLC

12/06/17

Common Stock

500,000

Convertible Debt Conversion

EMA Financial

12/07/17

Common Stock

400,000

Convertible Debt Conversion

Lucas Hoppel

12/11/17

Common Stock

750,000

Convertible Debt Conversion

Power Up Lending Group

12/13/17

Common Stock

774,648

Convertible Debt Conversion

EMA Financial

12/14/17

Common Stock

400,000

Convertible Debt Conversion

Power Up Lending Group

12/14/17

Common Stock

579,151

Convertible Debt Conversion

Lucas Hoppel

12/15/17

Common Stock

750,000

Convertible Debt Conversion

EMA Financial

12/19/17

Common Stock

500,000

Convertible Debt Conversion

Power Up Lending Group

12/19/17

Common Stock

943,750

Convertible Debt Conversion

Lucas Hoppel

12/26/17

Common Stock

750,000

Convertible Debt Conversion

Auctus Fund

12/27/17

Common Stock

500,000

Convertible Debt Conversion

Crown Bridge Partners, LLC

12/27/17

Common Stock

850,000

Convertible Debt Conversion

EMA Financial

12/28/17

Common Stock

1,000,000

Convertible Debt Conversion

Lucas Hoppel

12/28/17

Common Stock

1,031,122

Convertible Debt Conversion

Steven Sadaka

12/29/17

Common Stock

500,000

Professional Services

John D. Lane

01/01/18

Common Stock

10,000

Professional Services

Auctus Fund

01/04/18

Common Stock

1,500,000

Convertible Debt Conversion

Crown Bridge Partners, LLC

01/04/18

Common Stock

1,000,000

Convertible Debt Conversion

Lucas Hoppel

01/04/18

Common Stock

2,040,600

Inducement to secure a debt note

EMA Financial

01/08/18

Common Stock

1,600,000

Convertible Debt Conversion

Anthony Santelli, II

01/09/18

Common Stock

2,500,000

Purchased @ $0.03 per share

Richard Bindler Revocable Trust

01/09/18

Common Stock

2,500,000

Purchased @ $0.03 per share

Steven Sadaka

01/09/18

Common Stock

2,500,000

Purchased @ $0.03 per share

Vecchitto FLP Valori, LLC

01/09/18

Common Stock

2,500,000

Purchased @ $0.03 per share

Lucas Hoppel

01/22/18

Common Stock

2,000,000

Convertible Debt Conversion

EMA Financial

01/25/18

Common Stock

2,106,178

Convertible Debt Conversion

Auctus Fund

01/31/18

Common Stock

1,800,000

Convertible Debt Conversion

Lucas Hoppel

02/01/18

Common Stock

1,500,000

Convertible Debt Conversion

John D. Lane

02/01/18

Common Stock

10,000

Professional Services

Lucas Hoppel

02/06/18

Common Stock

1,000,000

Convertible Debt Conversion

Auctus Fund

02/09/18

Common Stock

716,356

Convertible Debt Conversion

Lucas Hoppel

02/12/18

Common Stock

1,500,000

Convertible Debt Conversion

Lucas Hoppel

02/15/18

Common Stock

1,239,171

Convertible Debt Conversion

Lucas Hoppel

02/21/18

Common Stock

500,000

Inducement to secure a debt note

Steven Sadaka

02/28/18

Common Stock

2,000,000

Inducement to secure a debt note

John D. Lane

03/01/18

Common Stock

10,000

Professional Services

Crown Bridge Partners, LLC

03/02/18

Common Stock

1,323,040

Convertible Debt Conversion

John D. Lane

04/01/18

Common Stock

10,000

Professional Services

The securities issued in the above mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(2) of that Act and Rules 505 and 506 of Regulation D.

Purchases of Equity Securities

The Company has never purchased nor does it own any equity securities of any other issuer.

ITEM 6. SELECTED FINANCIAL DATA

As a smaller reporting company it is not required to provide the information required by this Item.

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion should be read in conjunction with the Company’s audited financial statements and the notes thereto.

Forward-Looking Statements

This annual report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,” “anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of “penny stocks” and other risks and uncertainties. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement.

Business Overview

Alliance Bioenergy Plus, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels and new technologies sectors. In December 2013, a wholly owned subsidiary of the Company, AMG Renewables, LLC (“AMG Renewables”), acquired the controlling interest (51%) in AMG Energy Group, LLC (“AMG Energy”) and the remaining 49% was then acquired in 2016. AMG Energy Group owns a 50% interest of Carbolosic, LLC (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™.” The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The Company’s goal in acquiring the interest in AMG Energy is to develop the CTS technology to a commercial scale and then seek to license the technology to prospective licensees.

Plan of Operation

The Company is focused on the development and commercialization of the licensed technology it controls through its affiliate Carbolosic, LLC. Through its wholly owned subsidiary, AMG Energy, the Company owns Ek Laboratories, Inc. and a 50% interest in Carbolosic (which includes certain licensing rights in North America and Africa). The Company has a strategy that includes mergers and acquisitions of existing businesses in the renewable energy and sustainable products industries as well as sublicensing its patented technologies that it controls through a master license with the University of Central Florida under affiliate Carbolosic and start-up activities which are focused on development of an increasing revenue stream, secure market share and enhancement of shareholder value.

AMG ENERGY GROUP, LLC

AMG Energy, a wholly owned subsidiary of the Company, was created for the purpose of holding, managing, and developing the Company’s renewable energy technology enterprises. These interests comprise ownership of: (i) 100% of EK Laboratories, Inc., a Florida corporation (“EK”) (formerly known as Central Florida Institute of Science and Technology, Inc.); and (ii) a 50% interest in Carbolosic, LLC, a Delaware limited liability company (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™.” The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The Company’s goal is to develop this CTS technology to a commercial scale and then seek to acquire existing bioenergy and ethanol plants to install the CTS technology as well as license the technology to prospective licensees. EK was formed to serve as a pilot plant and research facility to further develop the CTS process, its uses, and develop new technologies.

ALLIANCE BIO-PRODUCTS, INC.

Alliance Bio-Products, a wholly owned subsidiary of the Company, was created for the purpose of acquiring and operating a plant for the installation of the Company’s patented CTS process.

In March 2017, the subsidiary commenced a $10,000,000 equity raise through an offering of 1 million units valued at $10 per share. Each unit consists of one share of 8% convertible preferred stock, with a preferred minimum investment of $5,000. The purpose of the offering is to secure funds through accredited investors for the purchase of a bioethanol plant in Southeast Florida that would enable the Company to increase production capacity and profitability of its sustainable, environmentally-friendly alternative to petroleum-based fuels and other products through its patented Cellulose to Sugar (CTS) conversion process.

In July 2017, Alliance Bio-Products, Inc., and ArborOne, ACA (representing the United States Department of Agriculture) offered to purchase the former INEOS Bio-Ethanol plant in Vero Beach, Florida, at a purchase price of $8 million. The purchase offer provides for the purchase of: (i) the fully functional Plant; (ii) over 143 acres on which the plant resides; and (iii) all related equipment and vehicles. In connection with the purchase offer, the subsidiary tendered the first initial deposit of $250,000. The transaction is subject to due diligence and the negotiation and execution of a definitive purchase agreement and other transaction documents.

As of this date, no units have been sold through the offering and the first initial deposit, in the amount of $250,000, has been refunded to the subsidiary.

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization as well as bio-fuels, renewable energy, chemical manufacturing, engineering and industrial construction industries. As of this date, the Company has generated $134,319 in revenue, however it has not generated any revenues from its core business.

Capital Formation

In April 2016, the Company entered into a 12-month convertible debenture with JMJ Financial. To obtain the note, the Company issued the holder 1,388,886 warrants with a five year term and a cashless exercise price equal to the lesser of $0.30 per share or the lowest trade price in the 10 preceding trading days. In the year ending December 31, 2016, JMJ Financial exercised its warrant agreement ratchet rights, thus rescinding 1,388,886 warrants and reissuing 3,067,668 warrants. SEE NOTE 5. There have been no ratchet right adjustments during the year ended December 31, 2017. As of December 31, 2017, and December 31, 2016, the holder had exercised all 3,056,625 and 11,043 warrants to acquire 1,340,201 and 11,043 shares of Company common stock, respectively. JMJ Financial’s warrant agreement has been fully exercised.

In October 2016, the Company commenced a new offering of units valued at $0.20 per share. Each unit consist of one share of common stock and a five year Series E warrant convertible to one common share at an exercise price of $0.45. From January 1, 2017, through the date of filing and at December 31, 2016, the Company has sold 4,687,500 and 2,200,050 units for aggregate proceeds of $987,500 and $390,010, respectively. The offering is ongoing.

In January 2018, The Company commenced a new offering of units valued at $0.03 per share. Each unit consist of one share of common stock. Through the date of filing, the Company has sold 10,000,000 units for aggregate proceeds of $300,000. The offering is ongoing.

From January 1, 2017 through the date of filing, the Company issued an aggregate of 7,666,632 shares of its common stock for services valued at $717,556.

From January 1, 2017 through the date of filing, the Company issued an aggregate of 1,700,000 warrants for services. Using a Black-Scholes asset-pricing model, these warrants were valued at $165,199. These warrant agreements have terms of five years with exercise prices ranging from $0.35 to $2.00 per share.

From January 1, 2017 through the date of filing, the Company issued options to its employees and independent directors to purchase an aggregate of 41,377,363 shares of common stock for a period of five years at an exercise price of $0.03, of which 35,377,363 are fully vested and the remaining 6,000,000 options vest over the next five years. Using a Black-Scholes asset-pricing model, these agreements were valued at $1,484,297. In addition, the Company rescinded 500,000 shares of common stock issued to a former employee under the Employee, Director Plan.

From January 1, 2017 through the date of filing, principal and interest in the amount of $915,160 was converted into 34,504,407 shares of common stock. The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of the convertible debt instruments set out above, the fair value of the stock was greater than the conversion price, and therefore a total value of $1,075,192 was attributed to the beneficial conversion features.

Going Concern

The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further equity. At December 31, 2017 the Company had a working capital deficiency of $3,325,275 and had incurred accumulated losses of $36,084,930 (of which approximately $26,345,921 is non-cash) since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, the report of the Company’s independent registered public accounting firm on the Company’s financial statements for the period ended December 31, 2017 contains an emphasis of matter paragraph regarding the Company’s ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. Furthermore, these financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.

Through its private offerings, the Company raised $3,079,004 for the year ended December 31, 2016 and an additional $1,007,501 in the year ended December 31, 2017. As of the date of filing, the company has received an additional $300,000 through its private offerings.

Results of Operations

Comparison of the year ended December 31, 2017 to December 31, 2016

For the year ended December 31, 2017, the Company recognized $134,319 in revenue as opposed to zero in all prior years. This revenue was the result of the sale of a bolt-on engineering package to a potential licensee, however this is not part of the Company’s core business. Throughout 2016, the Company capitalized $260,497 in connection with the engineering design and plans package for the bolt-on unit. With the nonrefundable sale of this first package, the Company has placed this capital expenditure into service and is amortizing the costs over three years. Therefore, as of December 31, 2017 and December 31, 2016, $7,236 and $0 have been expensed respectively.

For the year ended December 31, 2017 the Company’s general and administrative expenses increased by $710,791 to $4,311,499 from $3,600,708 for the year ended December 31, 2016. This increase is primarily the result of a $993,237 increase in payroll as consultants were hired as employees. This is reflected in a reduction in professional and consulting expenses of $56,511 from $1,965,767 to $1,909,526 of which $1,437,810 is non-cash stock compensation. Simultaneously, the Company recognized a $201,713 decrease in marketing expenses from $37,553 to $15,234.

Interest expense decreased in the year ended December 31, 2017 by approximately $372,683 to $902,918 from $1,275,601. This decrease was primarily the result of several debentures reaching maturity and also converting to common stock. Approximately $692,085 of principal and interest in short-term debt notes converted during the year.

For the year ended December 31, 2017 the Company’s equity loss in an unconsolidated affiliate increased by approximately $35,570 to $194,688 from $159,118 in 2016. This increase can be attributed to the Company’s maintenance of its patent portfolio and its worldwide patent protection. In addition, during the years ended December 31, 2017 and December 31, 2016, the Company recorded non-cash impairments of $4,069,995 and $3,207,701 respectively.

For the year ended December 31, 2017, the Company’s extinguishment of debt decreased by approximately $1,204,034 to a gain of $675,524 from an expense of $528,510 at December 31, 2016. During the same period, the Company’s change in fair value of its derivative instruments increased by approximately $846,695 to $854,008 at December 31, 2017 from $7,313 at December 31, 2016.

For the year ended December 31, 2017, the Company’s discontinued operations showed a loss of $2,400, as opposed to a $1,160,484 gain during the year ended December 31, 2016. This loss is primarily the result of legal fees, whereas the gain in 2016 was the result of the disposal of a subsidiary. These amounts are the result of the Company’s decision to divest the Company of its entertainment-related assets and subsidiaries and to focus all of the Company’s resources and personnel on the Company’s renewable energy holdings and future energy technologies.

Research and development (R&D) costs for the year ended December 31, 2017 were $736,750 an increase of $37,957 from $698,793 for the year ended December 31, 2016. The increase in R&D expenses is the result of the opening of Alliance BioProducts and its pursuit of developing the commercialization of the CTS process either through a stand alone facility or a portable bolt on unit.

Liquidity and Capital Resources

Liquidity

As of December 31, 2017 the Company had $55,076 in cash and total stockholders’ equity at December 31, 2017 was $780,265. Total debt from continuing operations, including advances, accounts payable and other notes payable at December 31, 2017, together with interest payable thereon, was $3,773,445 an increase of $132,453 from $3,640,992 at December 31, 2016. This increase is attributable to the addition of approximately $460,554 in convertible debt and a $141,432 increase in accrued liabilities.

During the fiscal year ended December 31, 2017, the Company’s continuing operating activities decreased $399,881 to $1,841,827 from $2,241,708 at December 31, 2016. This change can primarily be attributed to $793,921 used in payroll, $132,862 in legal, accounting and consulting fees, $56,054 in rent fees and $1,102,858 used in research and development .

During the fiscal year ended December 31, 2017, the Company’s investing activities used $167,128 in cash. This use can be attributed to $8,000 used to purchase machinery and equipment and $160,964 advanced to Carbolosic, LLC for operational costs. In addition, $250,000 was deposited in connection with the purchase of the Vero Beach plant purchase; however these funds were returned to the Company in September 2017.

During the fiscal year ended December 31, 2017, the Company generated an aggregate of $2,016,751 through its financing activities. This decrease of $421,280 from the prior year can primarily be attributed to a $2,071,504 decrease in the sale of common stock through the Company’s private offerings, while simultaneously securing $1,302,750 in short-term convertible debt notes during the year. During the same period, the Company repaid $323,500 principal of its short-term debt.

Capital Resources

At this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate revenue or obtain additional fincancing for current and future operations. As of the date of filing, the Company has raised $300,000, in addition to $7,816,894 raised through December 31, 2017, for a total of $8,116,894 through its private placement offerings. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to the Company.

The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations.

Critical Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control. Intercompany transactions and balances were eliminated in consolidation.

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in the Consolidated Statements of Earnings.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

Stock Compensation

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for under in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Accounting for Derivative Instruments

The Company issues debentures where the number of shares into which a debenture can be converted is not fixed. For example, when a debenture converts at a discount to market based on the stock price on the date of conversion. In such instances, the embedded conversion option of the convertible debentures is bifurcated from the host contract and recorded at their fair value. In accounting for derivatives, the Company records a liability representing the estimated present value of the conversion feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated with the beneficial conversion feature. The discount is then amortized over the life of the debenture and the derivative liability is adjusted periodically according to stock price fluctuations. At the time of conversion, any remaining derivative liability is charged to additional paid-in capital. For purposes of determining derivative liability, the Company uses Black-Scholes modeling for computing historic volatility.

Research and Development

The Company expenses all research and development costs as incurred. For the years ended December 31, 2017 and 2016, the amounts charged to research and development expenses were $736,750 and $698,793 respectively

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Seasonality

The Company’s operating results are not affected by seasonality.

Inflation

The Company’s business and operating results are not affected in any material way by inflation.

Contractual Obligations

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Set forth below are the audited financial statements for the Company for the years ended December 31, 2017 and December 31, 2016, and the report thereon of Paritz & Co., P.A.

Index to Financial Statements Page

	Page
Report of Independent Registered Public Accounting Firm	F-2

Consolidated Balance Sheets as of December 31, 2017 and December 31, 2016	F-3

Consolidated Statements of Operations for the years ended December 31, 2017 December 31, 2016	F-4

Consolidated Statements of Changes in Stockholder’s Equity for the years ended December 31, 2017 and December 31, 2016	F-5

Consolidated Statements of Cash Flows for the years ended December 31, 2017 and December 31, 2016	F-6

Notes to the Consolidated Financial Statements	F-7

F-1

REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Alliance Bioenergy Plus, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Alliance Bioenergy Plus, Inc. (the Company) as of December 31, 2017 and 2016, and the related statements of operations, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has not generated any significant revenue, has recurring losses since inception and has a working capital deficiency of $3,325,275 at December 31, 2017 and may be unable to raise further equity. These factors, among others, raise substantial doubt regarding the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Paritz & Company, P.A.

We have served as the Company’s auditor since 2012.

Hackensack, NJ

April 17, 2018

F-2

Alliance BioEnergy Plus, Inc.

CONSOLIDATED BALANCE SHEETS

	December 31, 2017			December 31, 2016
ASSETS
Current assets
Cash and cash equivalents	$	55,076		$	49,680
Prepaid expenses		429,242			680,813
TOTAL CURRENT ASSETS		484,318			730,493

PROPERTY AND EQUIPMENT, AT COST, NET OF ACCUMULATED DEPRECIATION OF $219,228 AND $133,771 AT DECEMBER 31, 2017 AND DECEMBER 31, 2016, RESPECTIVELY		177,304			254,761

Other assets
Security deposits		21,705			16,305
Capitalized fees		253,261			260,497
Investment in and advances to an unconsolidated affiliate		3,653,270			7,756,989
TOTAL OTHER ASSETS		3,928,236			8,033,791
TOTAL ASSETS	$	4,589,858		$	9,019,045

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities	$	483,120		$	341,688
Short term note payable – Related party		2,073,126			2,073,126
Short-term note payable – Other		96,570			96,570
Convertible debentures payable – Other, net of discount of $138,800 and $73,334		548,883			88,329
Interest payable – Related Party		192,606			68,929
Interest payable – Other		144,386			58,350
Derivative liabilities		234,754			914,000
Current liabilities of discontinued operations		36,148			36,148
TOTAL CURRENT LIABILITIES AND TOTAL LIABLITIES		3,809,593			3,677,140

STOCKHOLDER’S EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding		-			-
Common stock; $0.001 par value; 500,000,000 shares authorized; 97,540,888 shares issued and outstanding at December 31, 2017 and 71,707,493 shares issued and outstanding at December 31, 2016		97,541			71,707
Stock Subscription Receivable		-			(75,000	)
Additional paid-in capital		36,767,654			31,167,713
Accumulated deficit		(36,084,930	)		(25,822,515	)
TOTAL STOCKHOLDER’S EQUITY		780,265			5,341,905

TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY	$	4,589,858		$	9,019,045

The accompanying notes are an integral part of these consolidated financial statements

F-3

Alliance BioEnergy Plus, Inc.

CONSOLIDATED STATEMENT OF OPERATIONS

	For The Year Ended			For The Year Ended
	December 31, 2017			December 31, 2016
Revenue:
Sales		134,319			-
Cost of sales		-			-
Gross Revenue:	$	134,319		$	-

Operating expenses:
General and administrative		4,311,499			3,600,708
Research & development		736,750			698,793
Total operating expenses		5,048,249			4,299,501
Loss from operations:		(4,913,930	)		(4,299,501	)

Other (income) expense:
Equity loss in unconsolidated affiliates		194,688			159,118
Loss on impairment		4,069,995			3,207,701
Loss (gain) on extinguishment of debt		(675,524	)		528,510
Change in fair value of embedded derivative liability		854,008			7,313
Interest expense – related party		123,737			59,892
Interest expense and prepayment penalties – other		779,181			1,215,709
Total other (income) expense		(5,346,085	)		(5,178,243	)
Loss from continuing operations:		(10,260,015	)		(9,477,744	)

Discontinued operations:
Loss from operations		2,400			3,125
Gain on disposal of subsidiary		-			(1,163,609	)
Income (Loss) on discontinued operations:		(2,400	)		1,160,484

Net loss:		(10,262,415	)		(8,317,260	)
Net loss attributable to non-controlling interest:		-			452,458
Net loss attributable to Company:	$	(10,262,415	)	$	(8,769,718	)

Basic and diluted net loss per share:
Continuing operations		(0.13	)		(0.16	)
Discontinued operations		-			(0.02	)
Net loss per share:	$	(0.13	)	$	(0.14	)

Weighted average common shares outstanding:
Basic and Diluted		77,601,402			57,623,600

The accompanying notes are an integral part of these consolidated financial statements

F-4

Alliance BioEnergy Plus, Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY


	Common Stock						Preferred Stock				Stock Subscription			Additional Paid -in		Accumulated			Non-controlling			Total Stockholder’s
	Shares			Amount			Shares		Amount		Receivable			Capital		Deficit			Interest			(Deficiency)
Balance as of January 1, 2015		41,084,279		$	41,084			-		-	$	(5,000	)	$	21,160,997	$	(17,052,797	)	$	(452,458	)	$	3,691,826
Issuance of common stock for services		1,752,481			1,752			-		-		-			635,964		-			-			637,716
Issuance of common stock in connection with warrant conversion		11,043			11			-		-		-			4,802		-			-			4,813
Issuance of 4,496,648 warrants for services		-			-			-		-		-			1,188,632		-			-			1,188,632
Issuance of common stock for an acquisition (1)		10,240,094			10,240			-		-		-			3,481,387		-			-			3,491,627
Issuance of common stock and warrants for cash through PPM		14,671,136			14,672			-		-		(70,000	)		3,134,333		-			-			3,079,005
Issuance of 2,747,057 options under employee, director plan		-			-			-		-		-			558,720		-			-			558,720
Issuance of common stock in connection with conversion of notes payable		3,948,460			3,948			-		-		-			996,352		-			-			1,000,300
Disgorgement of short swing stock profits		-			-			-		-		-			6,526		-			-			6,526
Net loss		-			-			-		-		-			-		(8,769,718	)		452,458			(8,317,260	)
Balance as of December 31, 2016		71,707,493		$	71,707			-		-	$	(75,000	)	$	31,167,713	$	(25,822,515	)	$	-		$	5,341,905
Issuance of common stock for services		3,086,032			3,086			-		-		5,000			524,829		-			-			532,915
Issuance of 1,620,000 warrants for services		-			-			-		-		-			163,165		-			-			163,165
Issuance of common stock and warrants for cash through PPM		4,687,500			4,688			-		-		70,000			932,813		-			-			1,007,501
Issuance of 12,739,973 warrants under anti-dilution agreement		-			-			-		-		-			652,388		-			-			652,388
Issuance of 34,940,605 options under the employee, director plan		-			-			-		-		-			1,464,297		-			-			1,464,297
Issuance of common stock in connection with conversion of notes payable		17,219,662			17,220			-		-		-			1,362,094		-			-			1,379,314
Issuance of common stock in connection with warrant conversion		1,340,201			1,340			-		-		-			499,855		-			-			501,195
Recission of common stock under employee, director plan		(500,000	)		(500	)		-		-		-			500		-			-			-
Net loss		-			-			-		-		-			-		(10,262,415	)		-			(10,262,415	)
Balance as of December 31, 2017		97,540,888		$	97,541			-		-	$	-		$	36,767,654	$	(36,084,930	)	$	-		$	780,265

(1)

Stock issued in conjunction with the acquisition of the remaining 49% ownership of AMG Energy Group

The accompanying notes are an integral part of these consolidated financial statements

F-5

Alliance BioEnergy Plus, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For The Year Ended			For The Year Ended
	December 31, 2017			December 31, 2016
Cash flows from operating activities
Net loss from continuing operations		(10,260,015	)		(9,477,744	)
Net income (loss) from discontinued operations		(2,400	)		1,160,484
Net loss	$	(10,262,415	)	$	(8,317,260	)
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization		85,457			73,852
Amortization of non-cash compensation		328,800			584,567
Extinguishment of debt		(675,524	)		528,510
Non-cash interest expense		-			783,536
Change in fair value of embedded derivative liability		854,008			7,313
Stock based compensation for services		359,291			568,799
Issuance of warrants for services		761,469			585,678
Stock based compensation awarded under employee, director plan		-			-
Issuance of options awarded under employee, director plan		1,464,297			558,720
Equity loss in an unconsolidated affiliates		194,688			159,118
Impairment of the license		4,069,995			3,207,701
Changes in operating assets and liabilities
Prepaid expenses		(3,286	)		27,351
Accrued interest – other		779,180			10,891
Accounts payable and accrued liabilities		199,813			140,000
Net cash (used in) operating activities – continuing operations		(1,841,827	)		(2,241,708	)
Changes in discontinued operations assets and liabilities
Gain on disposal of subsidiary		-			(1,163,609	)
Net cash (used in) operating activities – discontinued operations		(2,400	)		(3,125	))
Net cash (used in) operating activities		(1,844,227	)		(2,244,833	)

Cash flows from investing activities
Purchase of property and equipment		(8,000	)		(18,037	)
Security deposit		(5,400	)		2,660
Capitalized fees		7,236			(58,476	)
Investment in and advance to an unconsolidated affiliate		(160,964	)		(131,719	)
Net cash (used in) investing activities – continuing operations		(167,128	)		(205,572	)
Net cash (used in) investing activities – discontinued operations		-			-
Net cash (used in) investing activities		(167,128	)		(205,572	)

Cash flows from financing activities
Proceeds from short-term note payable – related party		30,000			-
Proceeds from short-term note payable – other		-			-
Proceeds from warrant exercise		-			1,500
Proceeds from issuance of common stock		1,007,501			3,079,005
Proceeds from issuance of convertible debt		1,302,750			500,000
Repayment of convertible debt		(293,500	)		(884,000	)
Repayment of short-term note payable – related party		(30,000	)		-
Repayment of short-term note payable – other		-			(265,000	)
Payment of accrued interest		-			-
Disgorgement of short-swing stock profits		-			6,526
Net cash provided by financing activities – continuing operations		2,016,751			2,438,031
Net cash provided by financing activities – discontinued operations		-			-
Net cash provided by financing activities		2,016,751			2,438,031

Net increase (decrease) in cash and cash equivalents		5,396			(12,374	)

Cash and cash equivalent at beginning of the year		49,680			62,054
Cash and cash equivalent at end of the year	$	55,076		$	49,680

Supplemental disclosure of cash flow information
Cash paid during the period for
Interest	$	65,355		$	512,046
Taxes		-			-

Supplemental schedule of non-cash activities
Conversion of convertible debenture to common stock	$	1,379,314		$	1,003,613
Common stock issued for future services		53,124			68,917
Warrants issued for future services		20,819			602,954
Common stock issued for an acquisition		-			3,491,627
Cashless warrant conversion		501,195			-
Common stock issued as inducement for convertible debt		120,500			-
Warrants issued as inducement for convertible debt		33,265			-

The accompanying notes are an integral part of these consolidated financial statements

F-6

Alliance BioEnergy Plus, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION

Commencing in March 2016, the Company restructured its energy-related holdings through the following transactions:

	(1)	In March 2016, AMG Renewables, a wholly owned subsidiary of the Company, sold its interest in Carbolosic Plant 1 to Carbolosic Energy 1, LLLP, an unrelated third party, in exchange for satisfaction of the outstanding $1,250,000 loan and $36,488 interest between Carbolosic Plant 1 and Carbolosic Energy 1, LLLP. In connection with the transaction, an amount which the Company had prepaid to Carbolosic Energy 1, LLLP ($122,879) for future marketing and interest was eliminated in the sale.

	(2)	In July 2016, the Company determined to restructure its energy holdings under a single wholly owned subsidiary (AMG Energy) such that AMG Energy would own: (i) the Company’s fifty percent (50%) interest of Carbolosic (which includes certain licensing rights in North America and Africa); and (ii) the Company’s 100% interest in EK Laboratories, Inc. Concurrently, the Company divested itself of its interest in Carbolosic Plant 1.

This restructuring was completed on September 19, 2016 when AMG Renewables merged into AMG Energy. Previously, the Company had completed transactions with certain related parties to acquire the remaining 49% of AMG Energy (which was not owned by the Company) in exchange for: (i) an aggregate of 10,240,094 shares of Company common stock; and (ii) a restructuring of the balance due under a cash payable to the minority AMG Energy Shareholders.

Plan of Operation

The Company is now developing and commercializing the licensed technology it controls through its unconsolidated affiliate Carbolosic, LLC. Through its wholly owned subsidiary, AMG Energy, the Company owns Ek Laboratories, Inc., and a 50% interest in Carbolosic (which includes certain licensing rights in North America and Africa). The Company has a strategy that includes the following:

	(1)	mergers and acquisitions of existing businesses in the renewable energy and sustainable products industries;

	(2)	sub-licensing patented technologies it controls through a master license with the University of Central Florida under affiliate Carbolosic; and

F-7

(3)

start-up activities focused on increasing the Company’s revenue stream, securing market share, and enhancing shareholder value.

NOTE 2 – GOING CONCERN

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue, has incurred losses since inception, has a working capital deficiency of $3,325,275 and may be unable to raise further equity. At December 31, 2017, the Company had incurred accumulated losses of $36,084,930 of which approximately $26,345,921 is non-cash, since its inception. The Company expects to incur significant additional liabilities in connection with its start-up activities. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty

The Company intends to raise additional capital, sell licenses to its CTS technology and continue constructing its full-scale demonstration facility which, once operational, is expected to generate cash flow in amounts sufficient to cover the Company’s operating expenses and debt service.

Through its private offerings, the Company raised $6,809,394 from inception through December 31, 2016 and an additional $1,007,500 in the year ended December 31, 2017.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in the Consolidated Statements of Operations.

Use of Estimates

F-8

Cash and Cash Equivalents

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

Stock Compensation

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

Stock-based Compensation Valuation Methodology

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

The stock compensation issued for services during the year ended December 31, 2017, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the year ended December 31, 2017:

	01/01/17			02/18/17			03/31/17			04/01/17			05/03/17			06/02/17			06/30/17			07/01/17			08/01/17
Risk-free interest rate		1.93	%		1.92	%		1.93	%		1.93	%		1.86	%		1.71	%		1.89	%		1.89	%		1.80	%
Expected life		5 years			5 years			5 years			5 years			5 years			5 years			5 years			5 years			5 years
Expected dividends		0	%		0	%		0	%		0	%		0	%		0	%		0	%		0	%		0	%
Expected volatility		140.36	%		138.54	%		137.11	%		137.11	%		137.74	%		136.48	%		140.06	%		140.06	%		139.54	%
ALLM common stock fair value	$	0.20		$	0.16		$	0.11		$	0.11		$	0.14		$	0.17		$	0.38		$	0.38		$	0.21

		08/11/17			09/01/17			9/15/17			09/30/17			10/01/17			11/01/17			12/01/17			12/29/17
Risk-free interest rate		1.78	%		1.73	%		1.81	%		1.92	%		1.92	%		2.01	%		2.13	%		2.20	%
Expected life		5 years			5 years			5 years			5 years			5 years			5 years			5 years			5 years
Expected dividends		0	%		0	%		0	%		0	%		0	%		0	%		0	%		0	%
Expected volatility		139.45	%		135.96	%		131.42	%		129.30	%		129.30	%		127.24	%		130.02	%		157.26	%
ALLM common stock fair value	$	0.19		$	0.17		$	0.18		$	0.19		$	0.19		$	0.15		$	0.06		$	0.02

F-9

Accounting and Reporting of Discontinued Operations

As required by the FASB ASC Subtopic 205.20, per ASU 2014-08, Discontinued Operations, a component of an entity or a group of components of an entity, or a business or nonprofit activity can be classified as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when any of the following occurs: (i) the criteria in paragraph 205.20.45.1E to be classified as held for sale is met (ii) the component is disposed of by sale, or (iii) the component is disposed of other than by sale in accordance with paragraph 360.10.45.15 (for example, by abandonment or in a distribution to owners in a spinoff). Certain components to be disposed of other than by sale shall continue to be classified as “held and used” until it is disposed of, per the requirements of ASC Subtopic 360.10. Depreciation on these assets ceases upon their classification as “held and used.” The Company adopted ASU No. 2014-08 effective September 1, 2014.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 7 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

Research and Development

Revenue Recognition

The Company follows FASB ASC 605 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from the sales of licensing agreements, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date and the revenue recorded at December 31, 2017 was derived from a nonrefundable sale of an engineering package sold to a potential licensee partner. Similar packages will continue to be sold to future licensee partners, however they will not be the Company’s primary source of revenue. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

	1.	persuasive evidence of an arrangement exists;
	2.	the product has been shipped or the services have been rendered to the customer;
	3.	the sales price is fixed or determinable; and,
	4.	collectability is reasonably assured.

Convertible Instruments

The Company evaluates and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

Accounting for Derivative Instruments

Common Stock Purchase Warrants and Other Derivative Financial Instruments

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

F-10

Non-controlling interest in consolidated subsidiaries

The accompanying consolidated financial statements include the accounts of Alliance BioEnergy Plus, Inc. and those subsidiaries that the Company has the ability to control either through voting rights or means other than voting rights. For these subsidiaries, the Company records 100% of the revenues, expenses, cash flows, assets and liabilities in its consolidated financial statements. For subsidiaries that the Company controls but hold less than 100% ownership, a non-controlling interest is recorded in the consolidated income statement to reflect the non-controlling interest’s share of the net income (loss), and a non-controlling interest is recorded in the consolidated balance sheet to reflect the non-controlling interest’s share of the net assets of the subsidiary.

Investments in non-consolidated affiliates

Investments in non-consolidated affiliates are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company’s ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company’s proportionate share of the investees’ net income or losses after the date of investment. When net losses from an investment are accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company’s share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred.

The Company’s investment in Carbolosic, LLC is accounted for using the equity method of accounting. The Company monitors its investment for impairment at least annually and make appropriate reductions in the carrying value if it determines that an impairment charge is required based on qualitative and quantitative information.

Impairment of Long Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

F-11

Profit (Loss) per Common Share:

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:

	December 31, 2016		December 31, 2017
Annual dividend yield		-		-
Expected life (years)		4.30		0.50 – 0.10
Risk-free interest rate		1.93%		1.04% - 0.98%
Expected volatility		24% - 163%		22% - 156%

Fair Value Measurements at

December 31, 2016

Using Fair Value Hierarchy

Level 1

Level 2

Level 3

Liabilities

Embedded derivative liabilities – (Warrant)

794,000

Embedded derivative liabilities – (Debenture)

120,000

Total

914,000

F-12

Fair Value Measurements at

December 31, 2017

Using Fair Value Hierarchy

Level 1

Level 2

Level 3

Liabilities

Embedded derivative liabilities – (Warrant)

Embedded derivative liabilities – (Debenture)

234,754

Total

234,754

For the year ended December 31, 2017, the Company recognized a loss of $854,008 on the change in fair value of its derivative liabilities. At December 31, 2017, the Company did not identify any other assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with ASC 825-10.

Recent Accounting Pronouncements

NOTE 4 – INVESTMENT IN UNCONSOLIDATED AFFILIATE

On December 26, 2013, AMG Renewables, LLC, a Florida limited liability company (“AMG Renewables”), a wholly-owned subsidiary of the Company, acquired the controlling interest (51%) in AMG Energy Group, LLC a Florida limited liability company (“AMG Energy”) from certain related parties and subsequently acquired the remaining 49% in 2016. AMG Energy owns a fifty percent (50%) interest of Carbolosic, LLC, a Delaware limited liability company (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™.” The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The results of AMG Renewables and AMG Energy are consolidated in the Company’s financial statements. AMG Energy’s investment in Carbolosic is accounted for using the equity method of accounting.

Due to a lack of revenue from the Company’s core business, the Company recorded a non-cash impairment loss on its investment in Carbolosic of $4,069,995 and $3,207,701 at December 31, 2017 and December 31, 2016 respectively. The impairment loss was determined by using an income approach through a discounted future adjusted net cash flow method.

The following is a condensed balance sheet of the unconsolidated affiliate as of December 31, 2017 and December 31, 2016 and a comparative statement of operations for the years ending December 31, 2017 and 2016.

Condensed Balance Sheet of Non-Consolidated Affiliate

	December 31, 2017			December 31, 2016
ASSETS
Current Assets
Cash and cash equivalents	$	100		$	199
TOTAL ASSETS	$	100		$	199

LIABILITIES AND STOCKHOLDERS EQUITY
Current Liabilities
Accounts payable and accrued liabilities	$	629,681		$	406,474
Interest payable		56,679			31,309
Current notes payable		798,288			657,585
TOTAL CURRENT LIABILITIES		1,484,648			1,095,369

STOCKHOLDERS EQUITY
Accumulated deficit		(1,484,548	)		(1,095,170	)
TOTAL EQUITY		(1,484,548	)		(1,095,170	)

TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	$	100		$	199

F-13

Condensed Statement of Operations of Non-Consolidated Affiliate

	For The Year Ended			For The Year Ended
	December 31, 2017			December 31, 2016

Revenues	$	-		$	-

Operating Expenses
Royalties		70,000			70,000
Legal fees		81,593			56,633
General and administrative		212,138			185,866
Total operating expenses		(363,731	)		(312,519	)

Other expenses
Interest expense		25,647			18,627
Total other expenses		(25,647	)		(18,627	)

Loss from operations	$	(389,378	)	$	(331,147	)

NOTE 5 – DEBT

Short Term Notes Payable—Related Parties

Throughout 2013, the Company issued unsecured short-term notes payable to various related parties, including officers and directors of the Company, with a term of one year, which have since been extended and are coming due June 1, 2018. As of December 31, 2017, there was one consolidated note outstanding to Palm Beach Energy Solutions, LLC. The note has an outstanding principal balance of $71,000 and bears interest at a rate of 5% per annum. As of December 31, 2017, and December 31, 2016, the total interest accrued on the note was $16,146 and $12,596 respectively.

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes have a value of $2,002,126 and accrue interest at a rate of six percent (6%) per annum. As of December 31, 2017, and December 31, 2016, the total interest accrued on the notes was $176,460 and $56,333 respectively. All of the notes were due on August 4, 2017 and are currently in default. However, the notes are held by related parties with the understanding that the notes are not to be paid until the Company begins generating profit.

In January and September 2017, the Company secured a $20,000 and $10,000 short-term bridge loan from a shareholder of the Company. These notes accrued interest at a rate of five percent (5%) per annum and were repaid within 30 days of issuance.

Short Term Notes Payable – Other

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note has a principal balance of $96,570 and accrues interest at a rate of six percent (6%) per annum. As of December 31, 2017, and December 31, 2016, the total interest accrued on the note was $8,588 and $2,794 respectively. The note was due on August 4, 2017 and is currently in default..

F-14

Convertible Debt

On April 25, 2016, the Company entered into a 12-month convertible debenture with JMJ Financial with a principal balance of $555,556. The note carries a 10% one-time interest charge, a 10% original issue discount, and a 75% warrant coverage of the amount funded, totaling an aggregate value of $416,666. The note may only be paid up to 98% of the balance due within the first 180 days at a 30% premium. After 180 days, the note cannot be repaid without the holder’s consent. The note is convertible after 180 days at a 25% discount to the lowest trade price in the preceding 10 trading days. Per the warrant coverage feature, the Company issued the investor 1,388,886 warrants with a 5-year term and a cashless exercise price equal to the lesser of $0.30 per share or the lowest trade price in the 10 preceding trading days. The warrant agreement also contains a down-round ratchet provision allowing the holder to increase its warrant count. The number of warrants to issue is calculated by dividing the aggregate value by the lower of $0.30 or the lowest trade price in the 10 preceding trading days. As of December 31, 2017, JMJ Financial has converted $466,080 into 3,670,000 shares of common stock. In addition, JMJ Financial has exercised its warrant agreement ratchet rights, resulting in 3,067,668 warrants outstanding. As of December 31, 2017, the holder had exercised warrants to purchase 11,043 of Company common stock and exercised its cashless conversion feature on the remaining warrants resulting in 1,340,201 shares of common stock issued. As of December 31, 2017, and December 31, 2016, these agreements were valued at $0 and $580,000 along with a total derivative liability of $20,000 and $334,000, respectively. This note is currently in default and is accruing compounding quarterly interest at a rate of eighteen percent (18%) per annum.

In January 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd., with a principal balance of $153,500 due and payable on or before October 29, 2017. The note carries an original issue discount of $3,500 and accrues interest at a rate of 12% per annum and is convertible into the Company’s common stock at a 39% discount on the average of the lowest three trading prices during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of 130% of the then outstanding principal and interest balance due, if the note is paid back within 180 days. In July 2017, the Company paid the debenture in full with a payment of $211,293, which represented a $153,500 principal payment and $57,593 in interest and penalties.

In February 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on October 2, 2017. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 150,000 inducement shares to secure the note, and may have to provide additional shares on the note’s six-month anniversary if the Company’s share price declines. These inducement shares were valued at $27,000 and are being amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. In the year ended December 31, 2017, the full principal and interest balance of $178,200 was converted into 1,960,991 shares of common stock.

In February 2017, the Company entered into a convertible debenture with Labry’s Fund LLP, with a principal balance of $140,000 due and payable on August 18, 2017. The note carries an original issue discount of $23,000 and accrues interest at a rate of 12% per annum and is convertible into the Company’s common stock at a 50% discount to the lowest trade price during the previous thirty trading days prior to the date of the note or prior to date of conversion, after 180 days, in whole or in part at the option of the holder. The note can be repaid, without prepayment penalties, within the first 180 days. In addition, the Company provided a warrant agreement to purchase up to 250,000 shares of common stock, with a term of 5 years and an exercise price of $0.35 per share of common stock. Using a Black-Scholes option-pricing model, this agreement was valued at $33,265 and is being amortized over the life of the agreement. In August 2017, the Company paid the debenture in full with a payment of $147,502, which represented a $140,000 principal payment and $7,502 in interest and penalties.

In April 2017, the Company entered into a convertible debenture with Auctus Fund, LLC with a principal balance of $117,750 due and payable on or before December 22, 2017. The note carries an original issue discount of $17,750, accrues interest at a rate of 12% per annum and is convertible into the Company’s common stock at a 50% discount on the lowest trading price during the twenty-five trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 90 days to a maximum of 135% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days. The conversion feature of this debenture has been valued and as of December 31, 2017 carries a derivative liability of $36,283. In the year ended December 31, 2017, principal in the amount of $103,150 converted into 2,200,000 shares of common stock.

F-15

In April 2017, the Company entered into a convertible debenture with EMA Financial, LLC with a principal balance of $150,000 due and payable on or before March 15, 2018. The note carries an original issue discount of $28,000, accrues interest at a rate of 10% per annum and is convertible into the Company’s common stock at a 35% discount on the lowest trading price during the 15 trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 90 days to a maximum of 130% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days. The conversion feature of this debenture has been valued and as of December 31, 2017, carries a derivative liability of $49,946. In the year ended December 31, 2017, principal in the amount of $125,641 converted into 3,750,000 shares of common stock.

In May 2017, the Company entered into a convertible debenture with Crown Bridge Partners, LLC with a principal balance of $58,000 due and payable on or before May 4, 2018. The note carries an original issue discount of $9,500, accrues interest at a rate of 10% per annum and is convertible into the Company’s common stock at a 40% discount on the lowest trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of 135% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days. The conversion feature of this debenture has been valued and as of December 31, 2017, carries a derivative liability of $33,525. In the year ended December 31, 2017, principal in the amount of $38,124 converted into 1,710,000 shares of common stock.

In May 2017, the Company entered into a convertible debenture with GS Capital Partners, LLC with a principal balance of $115,000 due and payable on or before May 9, 2018. The note carries an original issue discount of $5,750, accrues interest at a rate of 8% per annum and is convertible into the Company’s common stock at a 28% discount on the lowest trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 90 days to a maximum of 125% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days. In the year ended December 31, 2017, the full principal and interest balance of $119,663 converted into 4,531,122 shares of common stock.

In June 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd with a principal balance of $53,000 due and payable on or before March 20, 2018. The note carries an original issue discount of $3,000, accrues interest at a rate of 8% per annum and is convertible into the Company’s common stock at a 39% discount on the average lowest three day trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 60 days to a maximum of 130% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days. In the year ended December 31, 2017, the full principal and interest balance of $55,120 converted into 2,297,549 shares of common stock.

In July 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $110,000 due and payable on January 15, 2018. The note carries an 8% one-time interest charge, a $10,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 150,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $54,000 and are being amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. The conversion feature of this debenture has been valued and as of December 31, 2017, carries a derivative liability of $95,000.

In July 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd. with a principal balance of $153,000 due and payable on or before April 30, 2018. The note carries an original issue discount of $3,000 and accrues interest at a rate of 8% per annum and is convertible into the Company’s common stock at a 39% discount on the average of the lowest three trading prices during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of 130% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days.

F-16

In August 2017, the Company entered into a convertible debenture with Crown Bridge Partners, LLC with a principal balance of $58,000 due and payable on or before August 2, 2018. The note carries an original issue discount of $7,000, accrues interest at a rate of 10% per annum and is convertible into the Company’s common stock at a 40% discount on the lowest trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of 135% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days.

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carries an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $39,500 and are being amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due.

In December 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd. with a principal balance of $63,000 due and payable on or before September 30, 2018. The note carries an original issue discount of $3,000 and accrues interest at a rate of 8% per annum and is convertible into the Company’s common stock at a 39% discount on the average of the lowest three trading prices during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of 130% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days

Derivative Liabilities

The embedded conversion features of the above convertible notes payable and warrants contain discounted conversion prices and should be recognized as derivative instruments. Such embedded conversion features should be bifurcated and accounted for at fair value. As of the year ended December 31, 2017 and the year ended December 31, 2016, the Company had a derivative liability balance of $234,754 and $914,000, respectively. The Company uses the Black-Scholes option-pricing model to calculate derivate liability.

Fair Value of Embedded Derivative Liabilities:

December 31, 2015	$	-
Addition		1,275,547
Converted		(494,721	)
Change in Fair Market Value		7,313
As of December 31, 2016	$	914,000
Addition		656,119
Converted		(2,189,373	)
Changes in fair value of derivative liabilities		854,008
As of December 31, 2017	$	234,754

NOTE 6 – STOCKHOLDERS’ EQUITY

The total number of shares of capital stock, which the Company has authority to issue, is 510 million, 500 million of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). December 31, 2017, the Company had 97,540,888 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

F-17

In March 2016, the Company began a fifth round of financing wherein each unit consist of three million seven hundred seventeen thousand seven hundred eighty-five (3,717,785) shares of common stock and four million five hundred thousand (4,500,000) series F warrants for a period of five (5) years at an exercise price of $0.25 per share. Each warrant is convertible into one (1) share of common stock. Each unit also has an antidilution protection clause of no more than 10%. As of December 31, 2017 and December 31, 2016, zero units and 2 units have been sold respectively. In December 2017, an additional 12,739,976 warrants were issued as a result of the antidilution protection clause. Using a Black-Scholes asset-pricing model, these warrants were valued at $652,388.

In April 2016, the Company entered into a 12-month convertible debenture with JMJ Financial. To obtain the note, the Company issued the holder 1,388,886 warrants with a five year term and a cashless exercise price equal to the lesser of $0.30 per share or the lowest trade price in the 10 preceding trading days. In the year ending December 31, 2016, JMJ Financial exercised its warrant agreement ratchet rights, thus rescinding 1,388,886 warrants and reissuing 3,067,668 warrants. SEE NOTE 5. There have been no ratchet right adjustments during the year ended December 31, 2017. As of December 31, 2017 and December 31, 2016, the holder had exercised all 3,056,625 and 11,043 warrants to acquire 1,340,201 and 11,043 shares of Company common stock respectively. JMJ Financial’s warrant agreement has been fully exercised.

In October 2016, the Company commenced a new offering of units valued at $0.20 per share. Each unit consist of one share of common stock and a five year Series E warrant convertible to one common share at an exercise price of $0.45. As of December 31, 2017, and December 31, 2016, the Company sold 4,687,500 and 2,200,050 units for aggregate proceeds of $1,007,500 and $390,010, respectively. The offering is ongoing.

In the year ended December 31, 2017, the Company issued an aggregate of 3,086,032 shares of its common stock for services valued at $532,915.

In the year ended December 31, 2017, the Company issued an aggregate of 1,620,000 warrants for services. Using a Black-Scholes asset-pricing model, these warrants were valued at $152,585. These warrant agreements have terms of five years with exercise prices ranging from $0.35 to $2.00 per share.

In the year ended December 31, 2017, the Company issued options under its Employee & Directors Stock Option Plan to purchase an aggregate of 34,940,605 shares of common stock for a period of five years at an exercise price ranging from $0.03 - $0.16. Using a Black-Scholes asset-pricing model, these agreements were valued at $1,464,297. In addition, the Company rescinded 500,000 shares of common stock issued to a former employee under the Employee, Director Plan.

In the year ended December 31, 2017, principal and interest in the amount of $692,085 was converted into 17,219,662 shares of common stock. The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of the convertible debt instruments set out above, the fair value of the stock was greater than the conversion price, and therefore a total value of $687,229 was attributed to the beneficial conversion features.

NOTE 7 – INCOME TAXES

The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended December 31, 2017 and 2016 to the Company’s effective tax rate is as follows:

	Years Ended
	December 31, 2017			December 31, 2016
Statutory federal income tax rate		-34	%		-34	%
State income tax, net of federal benefits		-6	%		-6	%
Valuation Allowance		40	%		40	%
Income tax provision (benefit)		0	%		0	%

F-18

The benefit for income tax is summarized as follows:

	Years Ended
	December 31, 2017			December 31, 2016
Federal
Current	$	-		$	-
Deferred		(3,489,221	)		(2,981,704	)
State
Current		-			-
Deferred		(615,745	)		(526,183	)
Change in valuation allowance		4,104,966			3,507,887
Income tax provision (benefit)	$	-		$	-

The tax effects of temporary differences that give rise to the Company’s net deferred tax liability as of December 31, 2017 and 2016 are as follows:

	Years Ended
	December 31, 2017			December 31, 2016
Deferred tax asset
Net operating loss carryovers	$	9,742,932		$	10,329,006
Total deferred tax assets		9,742,932			10,329,006
Valuation Allowance		(9,742,932	)		(10,329,006	)
Deferred tax asset, net of allowance	$	-		$	-

As of December 31, 2017 and 2016, the Company had $36,084,930 and $25,822,515 of Federal net operating loss carryovers (“NOLs”) to offset taxable income, if any, in future years which begin to expire in 2033. Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. The Company has estimated its provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance. As a result, it has recorded no income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted.

On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The deferred tax expense recorded in connection with the remeasurement of deferred tax assets is a provisional amount and a reasonable estimate at December 31, 2017 based upon the best information currently available. The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete. The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018.

The Company files U.S. Federal and Florida tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2012. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business.

F-19

Leases

The Company has leased office space pursuant to a lease for a period of 36 months from August 5, 2015, through July 31, 2018. Annual rent commenced at approximately $48,925 per annum and increases on a year-to-year basis by 3% over the base year. In addition, the Company is obligated to pay an amount equal to 3.76% of the operating expenses of the building together with sales tax on all amounts.

EK Laboratories leases office and warehouse space in Longwood, FL, which serves as the Company’s research and demonstration facility. The lease period is for 36 months from February 1, 2015, through January 31, 2018. Annual rent commences at approximately $70,620 per annum and increases on a year-to-year basis by 5% over the prior year. The Company also has the right to purchase the property during the lease term. The lease was not renewed.

Rent expense for the year ended December 31, 2017 and December 31, 2016 were $132,081 and $126,692 respectively.

As of December 31, 2017, the total future minimum lease payments in respect of leased premises are as follows:

YEAR ENDED	MINIMUM DUE
2018		63,586
2019		33,372
2020		34,373

TOTAL	$	131,331

NOTE 9 – RELATED PARTY TRANSACTIONS

Related Transactions

Short-term notes payable and convertible notes issued to related parties are described in NOTE 5.

In December 2017, EK Laboratories rented office and warehouse space from Royal Palm Dev I, LLC, a company owned by Joe Walsh who is a greater than 10% shareholder of the Company.

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

NOTE 10 – DISCONTINUED OPERATIONS

On September 1, 2014, the Company determined the need to focus its resources and personnel on the Company’s renewable energy holdings and future energy technologies and to divest the company of its entertainment-related assets and subsidiaries. The principal reasons for such action is the expense, liability and losses that have been generated by the entertainment-related assets and to provide a clear focus and direction to the Company moving forward. Specifically, the Board approved the divesting, selling off, closing down or discontinuing of the operations of its entertainment-related subsidiaries, including but not limited to Prelude Pictures Entertainment, LLC, AMG Live, LLC, AMG Restaurant Operations, LLC (including The New York Sandwich Co.), AMG Music, LLC, AMG Releasing, LLC and AMG Television, LLC.

In March 2016, AMG Renewables, a wholly owned subsidiary of the Company, sold its interest in Carbolosic Plant 1 to Carbolosic Energy 1, LLLP (an unrelated third party), in exchange for satisfaction of the outstanding $1,250,000 loan and $36,488 interest between Carbolosic Plant 1 and Carbolosic Energy 1, LLLP. In connection with the transaction, an amount which the Company had prepaid to Carbolosic Energy 1, LLLP ($122,879) for future marketing and interest was eliminated in the sale.

F-20

Below is a reconciliation of the total assets and liabilities of the discontinued operations, which are presented separately on the balance sheet.

	December 31, 2017		December 31, 2016

Carrying amounts of major classes of assets included as part of discontinued operations
Prepaid expenses		-		-
Total assets of the discontinued operation	$	-	$	-

Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts payable and accrued liabilities	$	36,148	$	36,148
Total liabilities of the discontinued operation	$	36,148	$	36,148

Below is a reconciliation of the net loss of the discontinued operations, which are presented separately on the statement of operations.

	December 31,
	2017			2016
Major line items constituting pretax profit (loss) of discontinued operations
Revenue	$	-		$	-
Selling, general and administrative		(2,400	)		(3,125	)
Gain on disposal of subsidiary		-			1,163,609
Income (loss) from discontinued operations	$	(2,400	)	$	1,160,484

NOTE 11 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date the financial statements were available to be issued. Based on this evaluation, the Company has identified the following subsequent events:

From December 31, 2017 through the date of filing, the Company issued 2,080,600 shares of common stock for services valued at $91,141.

From December 31, 2017 through the date of filing, 80,000 warrants issued for services vested. Using a Black-Scholes asset pricing model, these warrants were valued at $2,034.

From December 31, 2017 through the date of filing, $223,075 of principal and interest on short-term convertible notes converted into 17,284,745 shares of common stock.

In January 2018, the Company entered into a convertible debenture with Power Up Lending Group, Ltd. with a principal balance of $128,000 due and payable on or before October 20, 2018. The note accrues interest at a rate of twelve percent (8.0%) per annum and is convertible into the Company’s common stock at a 39% discount, after 180 days, in whole or in part at the option of the holder. The note also carried a prepayment penalty, adjusting every 30 days to a maximum of one hundred thirty percent (130%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

F-21

In February 2018, the Company entered into a convertible debenture with Crown Bridge Partners, LLC with a principal balance of $58,000 due and payable on or before February 2, 2019. The note carries an original issue discount of $7,000, accrues interest at a rate of 10% per annum and is convertible into the Company’s common stock at a 40% discount on the lowest trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of 135% of the then outstanding principal and interest balance due, if the note is paid back within the first 180 days.

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500 and are being amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due.

In February 2018, the Company entered into a short term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000 and are being amortized over the life of the note. If the note is not repaid at maturity, then an additional 5,000,000 shares of common stock will be due.

In March 2018, an aggregate of 1,687,702 Class A and Class B warrants expired.

F-22

ITEM 9. – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. – CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures

The Company is required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its chief executive officer (also its principal executive officer) and its chief financial officer (also its principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company’s management, including the Company’s President (“President”), the Company’s principal executive officer (“CEO”) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation the Company’s CEO, President and CFO concluded that the Company’s disclosure controls and procedures were not effective as of December 31, 2017 to a reasonable assurance level to enable the Company to record, process, summarize and report information required under the Securities and Exchange Commission’s rules in a timely fashion. This conclusion resulted from the lack of separation of duties within the Company.

(b) Management’s Report on Internal Control over Financial Reporting

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

	●	Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

	●	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

	●	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

As of December 31, 2017, management assessed the effectiveness of the Company’s internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013) and SEC guidance on conducting such assessments. Based on that evaluation, the Company concluded that, during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficiencies that existed in the design or operation of its internal controls over financial reporting that adversely affected its internal controls and that may be considered to be material weaknesses.

The matters involving internal controls and procedures that the Company’s management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board was (a) the lack of a functioning audit committee, (b) there are insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements, (c) there is a lack of expertise with US generally accepted accounting principles and SEC rules and regulations for review of critical accounting areas and disclosures and material non-standard transactions and (d) lack of effective oversight during the financial close process resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures. The aforementioned material weaknesses were identified by the Company’s management in connection with the review of its financial statements for the year ended December 31, 2017.

Management believes that the material weakness set forth above did not have an effect on its financial results. However, management believes that the lack of a functioning audit committee, coupled with not having individuals on staff or retainer with a thorough knowledge of US GAAP and SEC rules and regulations and lack of effective oversight on the financial close process results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in its financial statements in future periods.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by its registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.

Remediation Plan

Management is sensitive to the issues presented and intends to take appropriate action when the Company’s financial resources permit. Management intends to hire additional support staff when its financial resources permit and it will continue to review and make necessary changes to the overall design of its internal control environment.

(c) Reclassification of prior Period Financial Statements

Certain items previously reported have been reclassified to conform with the current year’s presentation.

(d) Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

ITEM 9B. – OTHER INFORMATION

None

PART III

ITEM 10. – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Directors, Executive Officers and Significant Employees

The following table sets forth information with respect to the Company’s directors and executive officers. Other than these persons, there are no significant employees.

Name	Age	Position and Offices
Daniel de Liege	51	Chief Executive Officer, President and Chairman
Benjamin Slager	55	Chief Technology Officer and Director
George D. Bolton	68	Director
Charles F. Sills	73	Director

Daniel de Liege became President, Secretary and a director of the Company in April 2012 and became Chief Financial Officer in April 2014. He has also served as Chief Executive Officer of the Company from April 2012 through February 2015 and April 2015 to present. Prior to founding the Company, Mr. de Liege has been the President and CEO of Prelude Pictures since 1997. Prior to that Mr. de Liege was President of 24/7 Entertainment from 1994 until 1997. Mr. de Liege attended Palm Beach State College and is on the Board of Directors of The Timothy Initiative, a not for profit organization.

Charles F Sills became a director of the Company in July 2015. Mr. Sills has extensive experience planning and directing international industrial, infrastructure, environmental and energy initiatives, having served as a member of the Danube Task Force, the governing council that ran the Danube Basin Environmental Restoration Program led by the World Bank, the European Bank for Reconstruction & Development and the UN Development Program, involving 13 countries from Austria to Moldova. He also served on the Japan-U.S. Joint Fund for Social & Economic Development in Central/Eastern Europe, the Helsinki Commission focused on the environmental clean-up of the Baltic Sea, the Kaliningrad Defense Conversion Initiative, and the NGO Delegation to NAFTA, where he helped draft the Environmental Supplements. Mr. Sills was responsible for securing major funding support for the Smithsonian Institute’s biodiversity preservation/cancer cure research program in Brazil’s Amazon region; for the Sassari, Sardinia symposium on ozone depletion organized by the International Council of Scientific Unions; and for the White House Presidential Awards program sponsored by the President’s Council on Sustainable Development.

Mr. Sills has been engaged in the renewable energy sector since the 1980’s, when he led the Martin Marietta Aerospace (now Lockheed Martin) team that won the contract for and installed the world’s largest (at that time) solar photovoltaic energy installation, under a pilot program co-funded by the U.S. and Saudi Arabian Governments; researched and wrote a worldwide survey of renewable energy technologies and commercialization opportunities; and testified before Congress on the need for pro-active U.S. Government support for advanced renewable energy R&D and demonstration programs. Currently, he serves on both the Defense & Security Advisory Committee and the International Advisory Committee for the American Council on Renewable Energy (ACORE); and serves as a Board Member and Advisor on Energy and Environment for the Eurasia Center/Eurasian Business Coalition, where he has planned and moderated conferences on “Doing Business with the BRICS (Brazil, Russia, India, China and South Africa)”, and energy and infrastructure investment opportunities associated with the “New Silk Road”.

He has extensive experience in Government Contracting, and an advocate for Small Business access to Federal and Military contracting opportunities, serving as a member of the U.S. Chamber of Commerce’s Small Business Council, and an observer to the White House sponsored Inter-Agency Task Force on Veterans Business Development. He is President of FED/Contracting LLC, a consultancy that assists Small Businesses in partnering with Prime Contractors, and helps the Prime Contractors qualify Veteran and Minority vendors as teammates for project opportunities with mandated Diversity Supplier content. Based on the U.S. Defense Dept. ‘Mentor-Protégé’ program that he managed, Trillacorpe Construction, a Service-Disabled Veteran-Owned Small Business, was awarded the 2010 Defense Department Nunn-Perry Award for “superior performance in the areas of business growth and return on investment, Government contracting, technical performance and quality management”.

George D. Bolton became a director of the Company in July 2015. Prior to becoming a director of the Company, Mr. Bolton is a seasoned business professional with significant experience in production agriculture. From the management of fertilizer and chemical plants, to the development and integration of a precision farming system for a national fertilizer and chemical distribution company, George has worked to develop and integrate new technologies for agriculture.

Recognizing the impact carbon intensity would have on agriculture, Mr. Bolton was one of the founders of AgCert International, and co-author of the first agricultural baseline methodology approved by the United Nations Framework Convention on Climate Change (UNFCC) AM0016: Greenhouse gas mitigation from improved animal waste management systems in confined animal feeding operations. Under his direction this methodology was the catalyst which allowed AgCert International to construct over 725 biodigesters impacting more than 94% of the qualifying concentrated animal feeding operations in Mexico and Brazil. The construction and operation of these biogiesters dramatically improved each farms local environment impact while also lowering their carbon intensity. The cooperation between AgCert and the local farmers enabled the use of the Clean Development Mechanism of the UNFCC to produce and market millions of certified emissions for the purchasers, as well as covering the costs of each farms biodigesters.

Benjamin Slager became a director in October 2016. Mr. Slager is a seasoned business professional with significant experience in corporate finance, venture capital, and entrepreneurship. He has a proven record in founding, developing and selling high tech companies.

Mr. Slager began his career in 1987 as a financial analyst with a venture capital firm, NesBic Holding BV, in Utrecht, the Netherlands. He also served as a market maker on the European Option Exchange in Amsterdam, while working for International Option Investment BV, in Amsterdam. In 1990, Mr. Slager turned his focus to sales and marketing while serving as a sales engineer and international sales director for NesBic Holding BV, in Utrecht. In 1993, Mr. Slager began a 19-year career as an entrepreneur and corporate CEO when he co-founded Microidentt Group AG, in Erfurt, Germany. Microidentt’s core business focus was on manufacturing, developing, marketing, and sales of smartcards, smartcard related products and industry identification transponders worldwide. Mr. Slager grew the company to a market capitalization of $60 million dollars while serving as its CEO.

Mr. Slager continued his career as an entrepreneur by developing and selling several technical innovation companies between 2006 and 2013. Mr. Slager founded and sold SolarExcel BV, which developed a patented solution and production process for increasing the performance of solar cells. He also founded and sold Novameer BV, which developed high tech and patented fibers for antiballistic and composite applications. Mr. Slager has served as an Advisory Board Member for Alloksys Life Sciences BV, a company specializing in therapeutics for anti-inflammation.

Mr. Slager received his Bachelor of Science in Chemical Engineering from Technical College of Chemical Engineering in Hilversum, the Netherlands, in 1985. He also received a degree in Business Administration from Nijenrode University for Business Administration in 1987.

Audit Committee and Audit Committee Financial Expert

Section 16(a) Beneficial Ownership Reporting Compliance.

Section 16(a) of the Securities Act of 1934 requires the Company’s officers and directors, and greater than 10% stockholders, to file reports of ownership and changes in ownership of its securities with the Securities and Exchange Commission. Copies of the reports are required by SEC regulation to be furnished to the Company. Based on management’s review of these reports during the fiscal year ended December 31, 2017, the Company does not believe that all reports required to be filed were filed on a timely basis.

Code of Ethics

The Company’s board of directors has adopted a code of ethics that its officers, directors and any person who may perform similar functions is subject to. The Code of Ethics does not indicate the consequences of a breach of the code. If there is a breach, the board of directors would review the facts and circumstances surrounding the breach and take action that it deems appropriate, which action may include dismissal of the employee who breached the code.

ITEM 11. – EXECUTIVE COMPENSATION

The Company’s compensation philosophy is based on its belief that its compensation programs should be aligned with stockholders’ interests and business objectives; reward performance; and be externally competitive and internally equitable. The Company seeks to achieve three objectives, which serve as guidelines in making compensation decisions:

	1.	Providing a total compensation package which is competitive and therefore enables it to attract and retain, high-caliber executive personnel;

	2.	Integrating compensation programs with its short-term and long-term strategic plan and business objectives; and

	3.	Encouraging achievement of business objectives and enhancement of stockholder value by providing executive management long-term incentive through equity ownership.

The Company may compensate its officers with cash compensation, common stock and common stock options. The Company has not established any quantifiable criteria with respect to the level of compensation, stock grants or options. Rather, the Board of Directors will evaluate cash, stock grants and stock options paid to similarly situated companies. The Company does not currently have a functioning compensation committee and the Company’s entire board of directors handles the functions that would otherwise be handled by a compensation committee.

With respect to stock grants and options which may be issued to the Company’s officers and directors, the Board will consider an overall compensation package that includes both cash and stock based compensation which would be in line with the Company’s overall operations and compensation levels paid to similarly situated companies. Under the Company’s 2012 Employee, Director Stock Plan, the administrator can provide for the grant of non-qualified stock options (“Non-Qualified Stock Options”), incentive stock options (“ISOs”, together with Non-Qualified Stock Options referred to herein as “Stock Options”), stock appreciation rights (“SARs”), restricted stock (“Restricted Stock”) and registered stock (“Registered Stock”), (collectively, the “Awards”) to eligible Participants.

The following table sets forth the compensation paid by the Company to its officers and directors for the fiscal years ended December 31, 2017 and 2016. This information includes the dollar value of base salaries, bonus awards and number of stock options granted, and certain other compensation, if any. The compensation discussed addresses all compensation awarded to, earned by, or paid to its named executive officers and directors.

Principal Position	Year		Salary		Bonus		Stock Awards		Option Awards		Non-Equity Incentive Plans		Non-Qualified Deferred Comp on Earnings		Other		Total

Daniel de Liege		2017		275,000		-		-		359,770		-		-		-	$	634,770
(President / CEO)		2016		240,000		-		-		239,378		-		-		-	$	479,348

Benjamin Slager		2017		55,000		-		-		586,158		-		-		-	$	641,158
		2016		-		-		-		10,000		-		-		-	$	10,000

George D. Bolton		2017		-		-		-		40,000		-		-		-	$	40,000
		2016		-		-		-		40,000		-		-		-	$	40,000

Charles F. Sills		2017		10,000		-		-		30,000		-		-		-	$	40,000
		2016		18,333						45,641							$	63,974

Outstanding Equity Awards at Fiscal Year End

In the years ended December 31, 2017 and December 31, 2016, the Company’s Chief Executive Officer received options to purchase up to 8,449,442 and 1,250,074 shares of company common stock, respectively, under the Company’s 2012 Employee Director Stock Plan at an exercise price of $0.03 per share and five-year terms. These awards were issued in accordance with the terms of the executive’s employment agreement. Using a Black-Scholes asset pricing model, these agreement were valued at $359,770 and 239,378 respectively.

In the years ended December 31, 2017 and December 31, 2016, the Company’s Chief Technology Officer received options to purchase up to 15,575,595 and 59,760 shares of company common stock, respectively, under the Company’s 2012 Employee Director Stock Plan at an exercise price of $0.03 per share and five-year terms. These awards were issued in accordance with the terms of the executive’s employment agreement. Using a Black-Scholes asset pricing model, these agreement were valued at $586,158 and $10,000 respectively.

In March 2015, the Company’s Board of Directors approved a resolution to compensate the board’s independent directors with cash or equity per quarter under the Company’s 2012 Employee, Director Stock Plan. During the fiscal years ended December 31, 2017 and December 31, 2016, the company issued to its current and former independent directors, option agreements to purchase an aggregate of 1,061,720 and 270,494 shares of common stock for a period of five (5) years at an exercise price of $0.03 valued at $70,000 and $60,000 respectively.

Additional Narrative Disclosures

A majority of the Company’s employees, including its executive officers, have entered into employment contracts with the company. The company does not offer any benefits package, deferred compensation or retirement plan at this time.

Director Compensation

In March 2015, the Board of Directors approved resolution to award compensation packages to the Company’s independent directors for their service as directors or as members of any committee of directors. Each independent member of the board is to receive $10,000 in value of common stock, cash or five-year options per quarter. In addition, the Chairman of the Board is to receive a $3,000 monthly payment. The Company may compensate its directors with common stock, common stock options, cash or a combination of these instruments. The Company has not established any quantifiable criteria with respect to the level of stock grants or options. Rather, the Board of Directors will evaluate stock grants and stock options paid to similarly situated companies.

ITEM 12. – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth certain information regarding beneficial ownership of the Company’s Common Stock as of the date of filing, by: (I) each current director; each nominee for director, and executive officer of the Company; (ii) all directors and executive officers as a group; and (iii) each shareholder who owns more than five percent of the outstanding shares of the Company’s Common Stock. Except as otherwise indicated, the Company believes each of the persons listed below possesses sole voting and investment power with respect to the shares indicated.

Name and Address	No of Shares (2)		% Owned (1)			Capacity
Daniel de Liege (3)		18,120,813		13.028	%	Chief Executive Officer
400 N. Congress Ave., Suite 130						President and Director
West Palm Beach , FL 33401

Benjamin Slager (5)		15,635,355		10.781	%	Chief Technology Officer
400 N. Congress Ave., Suite 130						Director
West Palm beach, FL 33401

Charles F. Sills		578,627		**		Director
400 N. Congress Ave., Suite 130
West Palm Beach, FL 33401

George D. Bolton		908,460		**		Director
400 N. Congress Ave., Suite 130
West Palm beach, FL 33401

All officers and directors as a group (four persons)

Joseph Walsh (4)		31,884,284		21. 877	%	5% Holder
400 N. Congress Ave., Suite 130
West Palm Beach, FL 33401

Anthony Santelli, II (7)		10,470,272		7.850	%	5% Holder
400 N. Congress Ave., Suite 130
West Palm Beach , FL 33401

Steven Sadaka (6)		11,380,683		8.580	%	5% Holder
3474 Derby Ln
Weston, FL 33331

Dennis Lenaburg (8)		10,932,777		7.791	%	5% Holder
400 N. Congress Ave., Suite 130
West Palm Beach , FL 33401

** less than one percent

	(1)	This table is based upon 129,396,233 shares of common stock issued and outstanding and 87,349,161 warrants and options vested and exercisable as of the date of filing.

	(2)	Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting and investment power with respect to the shares. Shares of Common Stock subject to options or warrants currently exercisable or exercisable within 60 days are deemed outstanding for computing the percentage of the person holding such options or warrants, but are not deemed outstanding for computing the percentage of any other person.

	(3)	Includes 7,421,297 shares and 9,699,516 fully vested and exercisable employee options owned by Daniel de Liege and an additional 1,000,000 shares owned by AFS Consulting, LLC the beneficial owner of which is Daniel de Liege.

	(4)	Includes 4,838,821 shares and 12,457,690 fully vested and exercisable warrants owned by United States Regional Economic Development Authority, LLC and 3,717,785 shares and 10,869,988 fully vested and exercisable warrants owned by Carbolosic Energy 1, LLLP of which the beneficial owner is Joseph Walsh. Joseph Walsh is a former Director of the Company.

	(5)	Includes 15,635,355 fully vested and exercisable employee options owned by Benjamin Slager. Benjamin Slager also has 1,00,000 additional employee options awarded and vesting over the next 2 years, unless the company enters into a merger or purchase agreement, at which time all shares shall vest immediately.

	(6)	Includes 8,140,341 shares and 3,240,342 fully vested and exercisable warrants owned by Steven Sadaka.

	(7)	Includes 2,760,136 shares and 260,136 fully vested and exercisable warrants owned by Anthony Santelli, II, 600,000 shares and 600,000 fully vested and exercisable warrants owned by AES Capital Partners, LP and 3,125,000 shares and 3,125,000 fully vested and exercisable warrants owned by The AES Capital Resource Fund, LP, the beneficial owner of which is Anthony Santelli, II.

	(8)	Includes 10,932,777 fully vested and exercisable employee options owned by Dennis Lenaburg. Dennis Lenaburg also has 5,000,000 additional employee options awarded and vesting over the next 5 years, unless the company enters into a merger or purchase agreement, at which time all shares shall vest immediately.

The Company is not aware of any person who owns of record, or is known to own beneficially, five percent (5%) or more of the outstanding securities of any class of the issuer, other than as set forth above.

Changes in Control

The Company does not currently have any arrangements which if consummated may result in a change of control of the Company.

ITEM 13. – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Related Transactions

	1)	Throughout 2013, the Company issued unsecured short-term notes payable to various related parties, including officers and directors of the Company, with a term of one year, which have since been extended. At December 31, 2017, there was one consolidated note outstanding to Palm Beach Energy Solutions, LLC. The note has an outstanding principal balance of $71,000 and bears interest at a rate of 5% per annum.

	2)	In July 2016, AMG Renewables, a wholly-owned subsidiary of the Company entered into an agreement to acquire, by merger, the remaining 49% of AMG Energy which it did not previously own by agreeing to issue 8,700,000 shares of new Company common stock to the holders of AMG Energy Solutions. Prior to the completion of this transaction, Solutions owned 43% of AMG Energy Group and two other parties controlled 6% of AMG Energy Group. This transaction was completed September 19, 2016. Following the merger, the Company owns 100% of AMG Energy, which in turn owns 100% of EK Laboratories, Inc. and 50% of Carbolosic. At the same time, the Company acquired the remaining 6% of AMG Energy from the remaining two parties in exchange for issuance of an aggregate of 1,540,094 shares of Company common stock. In addition, the remaining balance owed under the original transaction was renegotiated at an aggregate principal balance of $2,098,696 bearing an interest rate of six percent (6%) per annum and maturing on July 20, 2017. These notes have been extended until the earlier of: (i) an additional 12 months; or (ii) the Company’s first recorded revenue.

Following completion of the foregoing merger and acquisition of the minority interest, AMG Energy became a wholly-owned subsidiary of the Company. As a result, AMG Energy would become the holding company for all of the energy holdings of the Company (EK Laboratories, Inc. and a 50% interest in Carbolosic, which includes certain licensing rights in North America and Africa) and the existence of AMG Renewables ceased.

Director Independence

The Company currently has two (2) independent directors within the meaning of Nasdaq Marketplace Rule 4200. Although there are only two (2) independent directors, due to the business and financial expertise of the CEO and CTO, the company feels that the current board can competently perform the functions that an independent Board of Directors would provide.

ITEM 14. – PRINCIPAL ACCOUNTANT FEES AND SERVICES.

Audit Fees

The aggregate fees billed by the Company’s auditors, Paritz & Co. P.A. for professional services rendered for the audit of its annual financial statements for fiscal year ended December 31, 2017 and review its interim financial statements for the first, second and third quarters of 2018 will be approximately $65,000. The aggregate fees billed by the Company’s auditors, Paritz & Co P.A., for professional services rendered for the audit of its annual financial statements for fiscal year ended December 31, 2016 and review its interim financial statements for the first, second and third quarters of 2016 were approximately $56,600.

Audit Related fees

During the past fiscal year, no fees were billed or incurred for assurance or related services by the Company’s auditors that were reasonably related to the audit or review of financial statements reported above.

Tax Fees

During the past fiscal year, the Company incurred approximately $3,000 for tax preparation fees for the fiscal year ended December 31, 2016.

All Other Fees

During the past fiscal year, no other fees were billed or incurred for services by the Company’s auditors other than the fees noted above. The Company’s board, acting as an audit committee, deemed the fees charged to be compatible with maintenance of the independence of its auditors.

The Board of Directors Preapproval Policies

The Company does not currently have a functioning audit committee and the Company’s entire board of directors handles the functions that would otherwise be handled by an audit committee. The company expects to designate an audit committee of its board of directors in the near future. Before an independent auditor is engaged by the Company to render audit or non-audit services, the Company’s board of directors pre-approves the engagement. Board of directors pre-approval of audit and non-audit services will not be required if the engagement for the services is entered into pursuant to pre-approval policies and procedures established by the Company’s board of directors regarding its engagement of the independent auditor, provided the policies and procedures are detailed as to the particular service, its board of directors is informed of each service provided, and such policies and procedures do not include delegation of its board of directors’ responsibilities under the Exchange Act to its management. The Company’s board of directors may delegate to one or more designated members of its board of directors the authority to grant pre-approvals, provided such approvals are presented to the board of directors at a subsequent meeting. If the board of directors elects to establish pre-approval policies and procedures regarding non-audit services, the board of directors must be informed of each non-audit service provided by the independent auditor. Board of directors pre-approval of non-audit services, other than review and attest services, also will not be required if such services fall within available exceptions established by the SEC. For the fiscal year ended December 31, 2017, 100% of audit-related services, tax services and other services performed by the Company’s independent auditors were pre-approved by its board of directors.

The Company’s board has considered whether the services described above under the caption “All Other Fees”, which are currently none, is compatible with maintaining the auditor’s independence.

The board approved all fees described above.

PART IV

ITEM 15. – EXHIBITS, FINANCIAL STATEMENT SCHEDULES

The following documents are filed as part of this 10-K:

1. FINANCIAL STATEMENTS

The following documents are filed in Part II, Item 8 of this annual report on Form 10-K:

Report of Paritz & Co. P. A., Independent Registered Public Accounting Firm

Consolidated Balance Sheets as of December 31, 2017 and 2016

Consolidated Statements of Operations for the years ended December 31, 2017 and December 31, 2016

Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2017 and December 31, 2016

Consolidated Statements of Cash Flows for the years ended December 31, 2017 and December 31, 2016

Notes to the Consolidated Financial Statements

2. FINANCIAL STATEMENT SCHEDULES

All financial statement schedules have been omitted as they are not required, not applicable, or the required information is otherwise included.

3. EXHIBITS

The exhibits listed below are filed as part of or incorporated by reference in this report.

Exhibit No.		Identification of Exhibit

31.1.		Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2.		Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alliance BioEnergy Plus, Inc.
	(Registrant)

	By	/s/ Daniel de Liege
		Daniel de Liege
		Chief Executive Officer, President and Secretary (Principal Executive Officer)

	Date	April 17, 2018

	By	/s/ Daniel de Liege
		Daniel de Liege
		Chief Financial Officer (Principal Financial and Accounting Officer)

	Date	April 17, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated.

	By	/s/ Daniel de Liege
		Daniel de Liege
		Chief Executive Officer, Chief Financial Officer, President, Secretary and Director

	Date	April 17, 2018

	By	/s/ George D. Bolton
		George D. Bolton
		Director

	Date	April 17, 2018

	By	/s/ Charles F. Sills
		Charles F. Sills
		Director

	Date	April 17, 2018

	By	/s/ Benjamin Slager
		Benjamin Slager
		Director

	Date	April 17, 2018